首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma (see comments)
【24h】

Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma (see comments)

机译:局部晚期主要肝导管癌根治性切除术后辅助放疗的益处(见评论)

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: The objective of this study was to determine the benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma (Klatskin tumor). METHODS AND MATERIALS: We conducted a retrospective review of 63 patients who underwent surgical resection of Stage IVA Klatskin tumor. Of the 63 patients, 47 had microscopic tumor residue (RT1). Twenty-eight of the 47 patients with RT1 were treated by adjuvant radiotherapy and the remaining 19 patients were treated exclusively by surgical resection. Seventeen of the 28 patients with RT1 were treated by both intraoperative radiotherapy (IORT) and postoperative radiotherapy (PORT); of the remaining 11 patients with RT1, 6 underwent resection and IORT, and 5 underwent resection and PORT. RESULTS: The major complication and 30-day operative death rates were significantly lower in the radiation group (9.5% and 0.0%, respectively) than in the resection alone group (28.5% and 9.5%, respectively). Of the eight 5-year survivors with RT1, 6 had adjuvant radiotherapy and the remaining 2 had resection alone. Adjuvant radiotherapy for patients with RT1 yielded significantly (p = 0.0141) higher 5-year survival rates (33.9%) than in the resection alone group (13.5 %). The best 5-year survival rate (39.2 %) was found in patients who underwent a combination of IORT and PORT after resection. The local-regional control rate was significantly higher in the adjuvant radiation group than in the resection alone group (79.2% vs. 31.2%). CONCLUSION: Our data clearly suggest the improved prognosis of patients with locally advanced Klatskin tumor by integrated adjuvant radiotherapy with IORT and PORT to complete gross tumor resection with acceptable treatment mortality and morbidity.
机译:目的:本研究的目的是确定根治性切除局部晚期主肝导管癌(Klatskin肿瘤)后辅助放疗的益处。方法和材料:我们对63例行IVA Klatskin肿瘤手术切除的患者进行了回顾性回顾。在63例患者中,有47例具有微小的肿瘤残留(RT1)。 47例RT1患者中有28例接受了辅助放疗,其余19例仅接受了手术切除。在28例RT1患者中,有17例同时接受了术中放疗(IORT)和术后放疗(PORT)的治疗;其余11例RT1患者中,有6例接受了IORT切除术,有5例接受了PORT切除术。结果:放疗组的主要并发症和30天手术死亡率显着低于单纯切除组(分别为28.5%和9.5%)。在RT1的8位5年生存者中,有6位接受了辅助放疗,其余2位仅接受了切除。与单纯切除组(13.5%)相比,RT1患者的辅助放疗显着提高(p = 0.0141)5年生存率(33.9%)。切除后接受IORT和PORT联合治疗的患者,其5年生存率最高(39.2%)。辅助放疗组的局部区域控制率显着高于单纯切除组(79.2%比31.2%)。结论:我们的数据清楚地表明,通过联合辅助放疗联合IORT和PORT可以完成大体肿瘤切除,并具有可接受的治疗死亡率和发病率,局部晚期Klatskin肿瘤患者的预后得到改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号